Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Vir collaboration gives H.C. Wainwright more confidence in COVID-19 program » 11:13
01/27/21
01/27
11:13
01/27/21
11:13
VIR

Vir Biotechnology

$114.48 /

+37.99 (+49.67%)

, LLY

Eli Lilly

$208.50 /

-4.4 (-2.07%)

, GSK

GlaxoSmithKline

$38.73 /

-0.515 (-1.31%)

After Vir Biotechnology…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VIR Vir Biotechnology
$114.48 /

+37.99 (+49.67%)

LLY Eli Lilly
$208.50 /

-4.4 (-2.07%)

GSK GlaxoSmithKline
$38.73 /

-0.515 (-1.31%)

VIR Vir Biotechnology
$114.48 /

+37.99 (+49.67%)

07:00 Today JPMorgan
Vir Biotechnology downgraded to Underweight after 70% rally at JPMorgan
04:52 Today JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
01/20/21 H.C. Wainwright
Vir Biotechnology price target raised to $125 from $100 at H.C. Wainwright
12/24/20 Baird
Baird maintains 'profound skepticism' of Vir's COVID antibody after Lilly data
LLY Eli Lilly
$208.50 /

-4.4 (-2.07%)

01/26/21 Berenberg
Eli Lilly data 'incrementally positive' for AbCellera, says Berenberg
01/20/21 Citi
Citi opens 'positive Catalyst Watch' on Eli Lilly into Alzheimer's data
01/19/21 Roth Capital
Merus price target raised to $32 from $19 at Roth Capital
01/19/21
Fly Intel: Top five analyst upgrades
GSK GlaxoSmithKline
$38.73 /

-0.515 (-1.31%)

01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
01/20/21 UBS
GlaxoSmithKline price target raised to 1,450 GBp from 1,440 GBp at UBS
01/20/21
Fly Intel: Top five analyst downgrades
01/20/21 Credit Suisse
GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
VIR Vir Biotechnology
$114.48 /

+37.99 (+49.67%)

LLY Eli Lilly
$208.50 /

-4.4 (-2.07%)

GSK GlaxoSmithKline
$38.73 /

-0.515 (-1.31%)

  • 08
    Jul
VIR Vir Biotechnology
$114.48 /

+37.99 (+49.67%)

LLY Eli Lilly
$208.50 /

-4.4 (-2.07%)

GSK GlaxoSmithKline
$38.73 /

-0.515 (-1.31%)

VIR Vir Biotechnology
$114.48 /

+37.99 (+49.67%)

LLY Eli Lilly
$208.50 /

-4.4 (-2.07%)

GSK GlaxoSmithKline
$38.73 /

-0.515 (-1.31%)

LLY Eli Lilly
$208.50 /

-4.4 (-2.07%)

GSK GlaxoSmithKline
$38.73 /

-0.515 (-1.31%)

Recommendations
Johnson & Johnson price target raised to $175 from $157 at JPMorgan » 09:16
01/27/21
01/27
09:16
01/27/21
09:16
JNJ

Johnson & Johnson

$170.48 /

+4.47 (+2.69%)

JPMorgan analyst Chris…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

09:12 Today SVB Leerink
Johnson & Johnson price target raised to $200 from $180 at SVB Leerink
08:29 Today Credit Suisse
Johnson & Johnson price target raised to $193 from $168 at Credit Suisse
07:59 Today Cantor Fitzgerald
Johnson & Johnson price target raised to $200 from $180 at Cantor Fitzgerald
07:51 Today Wells Fargo
Johnson & Johnson price target raised to $190 from $175 at Wells Fargo
JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

Recommendations
Johnson & Johnson price target raised to $200 from $180 at SVB Leerink » 09:12
01/27/21
01/27
09:12
01/27/21
09:12
JNJ

Johnson & Johnson

$170.48 /

+4.47 (+2.69%)

SVB Leerink analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

08:29 Today Credit Suisse
Johnson & Johnson price target raised to $193 from $168 at Credit Suisse
07:59 Today Cantor Fitzgerald
Johnson & Johnson price target raised to $200 from $180 at Cantor Fitzgerald
07:51 Today Wells Fargo
Johnson & Johnson price target raised to $190 from $175 at Wells Fargo
07:44 Today Raymond James
Johnson & Johnson price target raised to $183 from $158 at Raymond James
JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

Hot Stocks
Sanofi's priority is to continue to develop two Covid vaccine candidates » 08:32
01/27/21
01/27
08:32
01/27/21
08:32
SNY

Sanofi

$49.15 /

-0.45 (-0.91%)

, GSK

GlaxoSmithKline

$39.24 /

+0.33 (+0.85%)

, TBIO

Translate Bio

$23.13 /

-1.5 (-6.09%)

Sanofi (SNY) is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TBIO Translate Bio
$23.13 /

-1.5 (-6.09%)

SNY Sanofi
$49.15 /

-0.45 (-0.91%)

GSK GlaxoSmithKline
$39.24 /

+0.33 (+0.85%)

SNY Sanofi
$49.15 /

-0.45 (-0.91%)

01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
01/15/21 Deutsche Bank
Sanofi initiated with a Sell at Deutsche Bank
01/08/21 Morgan Stanley
Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley
01/08/21 Morgan Stanley
Roche downgraded to Equal Weight from Overweight at Morgan Stanley
GSK GlaxoSmithKline
$39.24 /

+0.33 (+0.85%)

01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
01/20/21 UBS
GlaxoSmithKline price target raised to 1,450 GBp from 1,440 GBp at UBS
01/20/21
Fly Intel: Top five analyst downgrades
01/20/21 Credit Suisse
GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
TBIO Translate Bio
$23.13 /

-1.5 (-6.09%)

12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
SNY Sanofi
$49.15 /

-0.45 (-0.91%)

GSK GlaxoSmithKline
$39.24 /

+0.33 (+0.85%)

  • 26
    Jun
TBIO Translate Bio
$23.13 /

-1.5 (-6.09%)

SNY Sanofi
$49.15 /

-0.45 (-0.91%)

GSK GlaxoSmithKline
$39.24 /

+0.33 (+0.85%)

SNY Sanofi
$49.15 /

-0.45 (-0.91%)

GSK GlaxoSmithKline
$39.24 /

+0.33 (+0.85%)

Hot Stocks
Sanofi to provide support to BioNTech in manufacturing Covid vaccine » 08:31
01/27/21
01/27
08:31
01/27/21
08:31
SNY

Sanofi

$49.15 /

-0.45 (-0.91%)

, BNTX

BioNTech

$106.18 /

-4.355 (-3.94%)

, PFE

Pfizer

$37.31 /

+0.025 (+0.07%)

Sanofi (SNY) and BioNTech…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNY Sanofi
$49.15 /

-0.45 (-0.91%)

PFE Pfizer
$37.31 /

+0.025 (+0.07%)

BNTX BioNTech
$106.18 /

-4.355 (-3.94%)

SNY Sanofi
$49.15 /

-0.45 (-0.91%)

01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
01/15/21 Deutsche Bank
Sanofi initiated with a Sell at Deutsche Bank
01/08/21 Morgan Stanley
Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley
01/08/21 Morgan Stanley
Roche downgraded to Equal Weight from Overweight at Morgan Stanley
BNTX BioNTech
$106.18 /

-4.355 (-3.94%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
PFE Pfizer
$37.31 /

+0.025 (+0.07%)

01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
SNY Sanofi
$49.15 /

-0.45 (-0.91%)

PFE Pfizer
$37.31 /

+0.025 (+0.07%)

BNTX BioNTech
$106.18 /

-4.355 (-3.94%)

  • 23
    Jul
  • 06
    Feb
SNY Sanofi
$49.15 /

-0.45 (-0.91%)

PFE Pfizer
$37.31 /

+0.025 (+0.07%)

BNTX BioNTech
$106.18 /

-4.355 (-3.94%)

SNY Sanofi
$49.15 /

-0.45 (-0.91%)

PFE Pfizer
$37.31 /

+0.025 (+0.07%)

BNTX BioNTech
$106.18 /

-4.355 (-3.94%)

PFE Pfizer
$37.31 /

+0.025 (+0.07%)

BNTX BioNTech
$106.18 /

-4.355 (-3.94%)

Recommendations
Johnson & Johnson price target raised to $193 from $168 at Credit Suisse » 08:29
01/27/21
01/27
08:29
01/27/21
08:29
JNJ

Johnson & Johnson

$170.48 /

+4.47 (+2.69%)

Credit Suisse analyst…

Credit Suisse analyst Matt Miksic raised the firm's price target on Johnson & Johnson to $193 from $168 and keeps an Outperform rating on the shares. The analyst believes Q4 results showcase J&J's high-performance pharma portfolio. Miksic expects continued growth in Pharma to lead the J&J portfolio throughout 2021, supported by improving growth in Med Devices and stable performance in Consumer against challenging prior-year comps.

ShowHide Related Items >><<
JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

07:59 Today Cantor Fitzgerald
Johnson & Johnson price target raised to $200 from $180 at Cantor Fitzgerald
07:51 Today Wells Fargo
Johnson & Johnson price target raised to $190 from $175 at Wells Fargo
07:44 Today Raymond James
Johnson & Johnson price target raised to $183 from $158 at Raymond James
07:42 Today Cowen
Johnson & Johnson price target raised to $195 from $170 at Cowen
JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

Syndicate
Catalyst Biosciences 8.7M share Spot Secondary priced at $5.75 » 08:02
01/27/21
01/27
08:02
01/27/21
08:02
CBIO

Catalyst Biosciences

$6.29 /

-0.53 (-7.77%)

The deal range was…

The deal range was $5.75-$6.00. Piper Sandler acted as lead book running manager for the offering.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$6.29 /

-0.53 (-7.77%)

CBIO Catalyst Biosciences
$6.29 /

-0.53 (-7.77%)

12/02/20 Raymond James
Catalyst Biosciences gets Fast Track for MarzAA, says Raymond James
05/21/20 Raymond James
Catalyst Biosciences initiated with an Outperform at Raymond James
CBIO Catalyst Biosciences
$6.29 /

-0.53 (-7.77%)

  • 27
    Jan
  • 18
    Jun
  • 13
    Feb
Recommendations
Johnson & Johnson price target raised to $200 from $180 at Cantor Fitzgerald » 07:59
01/27/21
01/27
07:59
01/27/21
07:59
JNJ

Johnson & Johnson

$170.48 /

+4.47 (+2.69%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Louise Chen raised the firm's price target on Johnson & Johnson to $200 from $180 and keeps an Overweight rating on the shares following the company's "quality" Q4 beat and positive outlook for 2021, reflecting solid performance and positive trends across its diversified business model. The analyst continues to believe that upward earnings revisions and multiple expansion, driven by above-market growth in its key franchises and its diversified business model, should move shares higher.

ShowHide Related Items >><<
JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

07:51 Today Wells Fargo
Johnson & Johnson price target raised to $190 from $175 at Wells Fargo
07:44 Today Raymond James
Johnson & Johnson price target raised to $183 from $158 at Raymond James
07:42 Today Cowen
Johnson & Johnson price target raised to $195 from $170 at Cowen
07:24 Today Morgan Stanley
Johnson & Johnson price target raised to $187 from $178 at Morgan Stanley
JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

Recommendations
Johnson & Johnson price target raised to $190 from $175 at Wells Fargo » 07:51
01/27/21
01/27
07:51
01/27/21
07:51
JNJ

Johnson & Johnson

$170.48 /

+4.47 (+2.69%)

Wells Fargo analyst Larry…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

07:44 Today Raymond James
Johnson & Johnson price target raised to $183 from $158 at Raymond James
07:42 Today Cowen
Johnson & Johnson price target raised to $195 from $170 at Cowen
07:24 Today Morgan Stanley
Johnson & Johnson price target raised to $187 from $178 at Morgan Stanley
01/15/21 B. Riley Securities
Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

Recommendations
Johnson & Johnson price target raised to $183 from $158 at Raymond James » 07:44
01/27/21
01/27
07:44
01/27/21
07:44
JNJ

Johnson & Johnson

$170.48 /

+4.47 (+2.69%)

Raymond James analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

07:42 Today Cowen
Johnson & Johnson price target raised to $195 from $170 at Cowen
07:24 Today Morgan Stanley
Johnson & Johnson price target raised to $187 from $178 at Morgan Stanley
01/15/21 B. Riley Securities
Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

JNJ Johnson & Johnson
$170.48 /

+4.47 (+2.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.